VolitionRX Ltd
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $15.6M
- Price
- $1.44
- % Change (Daily % change from the live per-ticker quote feed.)
- +7.06%
- Volume
- 225.2K
Quote data as of 7:05 AM ET
About
VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.
Quick stats
Shares outstanding11.6M
Computed float9.9M
Float sourceUnknown
Cash runway (months)-1.3
Dilution risk—
Has warrants—
Has convertibles—
Active shelf (Shelf registration (e.g. Form S-3) currently in effect — the company is pre-cleared to issue and sell new shares quickly. A standing dilution risk.)—
Active ATM (At-the-market offering — a program to sell newly issued shares directly into the open market at prevailing prices, diluting existing holders over time.)—
Key info
SectorHealthcare
IndustryMedical - Specialties
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000093314
Websitehttps://volition.com
AI Summary
AI-generated2d agostandardbullishclinical trialVolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
VolitionRx released data showing its Nu.Q Cancer Assay offers significant prognostic value for newly diagnosed lung cancer patients, enabling better risk stratification and treatment selection.
The company completed clinical certification at Hospices Civils de Lyon and plans to submit a reimbursement dossier in France shortly, with a determination mandated within five months of admissibility.
Management estimates direct sales revenue of approximately €50 per test and is exploring licensing opportunities globally beyond France.
Red flags
- Paper is currently under peer review
- Reimbursement coverage is contingent on dossier admissibility